Separately, Brean Capital restated a buy rating and set a $4.00 target price on shares of Neuralstem in a research note on Monday, September 12th.
Neuralstem (NASDAQ:CUR) opened at 0.3199 on Friday. The firm’s market cap is $36.71 million. The firm’s 50-day moving average price is $0.27 and its 200-day moving average price is $0.40. Neuralstem has a 12 month low of $0.19 and a 12 month high of $1.43.
Neuralstem (NASDAQ:CUR) last announced its earnings results on Thursday, August 11th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.01. Neuralstem had a negative return on equity of 574.32% and a negative net margin of 173,849.97%. The firm earned $2.50 million during the quarter, compared to the consensus estimate of $2.50 million. Equities research analysts predict that Neuralstem will post ($0.17) earnings per share for the current year.
Several institutional investors have recently modified their holdings of the company. Sabby Management LLC bought a new position in shares of Neuralstem during the second quarter worth about $1,893,000. Vanguard Group Inc. boosted its position in shares of Neuralstem by 21.8% in the second quarter. Vanguard Group Inc. now owns 3,384,138 shares of the company’s stock worth $984,000 after buying an additional 606,500 shares during the last quarter. Finally, Blair William & Co. IL bought a new position in shares of Neuralstem during the second quarter worth about $122,000. 18.20% of the stock is owned by institutional investors and hedge funds.
Neuralstem Company Profile
Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.
Receive News & Ratings for Neuralstem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.